SB27 is named as an intervention in 2 current clinical trials in our Spain, Turkey, India, Germany, Brazil, Mexico, Japan, Poland and South Korea registers. None are recruiting at the moment. The most common phase is Phase 3. The lead sponsor is Samsung Bioepis Co., Ltd. The most-studied condition is Non-small Cell Lung Cancer Stage IV.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
NCT06348199 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Stage IV
|
Phase 3 | Active, closed | Samsung Bioepis Co., Ltd | India, Germany, Spain, Turkey, Brazil, Mexico, Japan |
|
A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy
NCT06268613 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage IIIA
|
Phase 1 | Active, closed | Samsung Bioepis Co., Ltd | Spain, Poland, Turkey, South Korea |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Samsung Bioepis Co., Ltd | 2 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our Spain, Turkey, India, Germany, Brazil, Mexico, Japan, Poland and South Korea registers name SB27 as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Samsung Bioepis Co., Ltd. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how SB27 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how SB27 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists SB27 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.